1211P A multicenter phase II study of atezolizumab monotherapy following definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma (EPOC1802)

Bando, H.; Kumagai, S.; Kotani, D.; Saori, M.; Habu, T.; Tsushima, T.; Hara, H.; Kadowaki, S.; Kato, K.; Chin, Keisho; Yamaguchi, K.; Kageyama, S-I.; Hojo, H.; Nakamura, M.; Tachibana, H.; Wakabayashi, M.; Fukutani, M.; Fuse, N.; Nishikawa, H.; Kojima, T.

doi:10.1016/j.annonc.2022.07.1329

Cited by 9 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2021, a single-arm, single-center, open-label, phase Ib clinical study of camrelizumab in combination with dCRT for the treatment of inoperable LA-ESCC showed that dCRT plus anti-PD-1 antibody is safe and feasible (69). In this study, 20 patients were included, with 2 patients showing complete response, 13 patients showing partial response, and 3 patients having stable disease status.…”

Section: Development Of Therapeutic Strategies For Inoperable La-escc...mentioning

confidence: 94%

Current and future on definitive concurrent chemoradiotherapy for inoperable locally advanced esophageal squamous cell carcinoma

Xie,

Cai,

Chen

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Esophageal squamous cell carcinoma (ESCC) is an aggressive and fatal disease that is usually diagnosed when the chances for surgical intervention has been missed. Definitive concurrent chemoradiotherapy (dCRT) is the first choice of treatment for inoperable locally advanced esophageal squamous cell carcinoma (LA-ESCC). Nevertheless, the local recurrence rate for esophageal cancer patients undergoing dCRT remains high at 40-60%, with a 5-year overall survival rate of solely 10-30%. Immunotherapy in combination with dCRT is a promising treatment for inoperable LA-ESCC, for that improved long-term survival is expected. The present review provides a comprehensive overview of the evolutionary trajectory of dCRT for LA-ESCC, delineates notable relevant clinical studies, addresses unresolved concerns regarding the combination of dCRT with immunotherapy, and highlights promising directions for future research. When dCRT is combined with immunotherapy, the following aspects should be carefully explored in the future studies, including the optimal irradiation dose, segmentation scheme, radiotherapy technique, timing, sequence and duration of radiotherapy, and the selection of chemotherapeutic and immunologic drugs. In addition, further investigations on the mechanisms of how dCRT combined with immunotherapy exerts synergistic anti-tumor effects and molecular biomarkers ensuring precise screening of ESCC patients are needed.

show abstract

Section: Development Of Therapeutic Strategies For Inoperable La-escc...mentioning

confidence: 94%

Current and future on definitive concurrent chemoradiotherapy for inoperable locally advanced esophageal squamous cell carcinoma

Xie,

Cai,

Chen

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…In a treatment with atezolizumab following dCRT, the confirmed CR was 40%, with median PFS of 3.2 months and OS of 31.0 months, in 40 patients. 304 In an interim analysis of anti-PD-1 mAb camrelizumab as a consolidation therapy after dCRT, 13 of 15 patients had stable disease. After a median follow-up period of 17 months, the median PFS and OS were not reached.…”

Section: Potent Strategies Of Definitive Chemoradiationmentioning

confidence: 99%

Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma

et al. 2023

View full text Add to dashboard Cite

Esophageal cancer (EC) remains a public health concern with a high mortality and disease burden worldwide. Esophageal squamous cell carcinoma (ESCC) is a predominant histological subtype of EC that has unique etiology, molecular profiles, and clinicopathological features. Although systemic chemotherapy, including cytotoxic agents and immune checkpoint inhibitors, is the main therapeutic option for recurrent or metastatic ESCC patients, the clinical benefits are limited with poor prognosis. Personalized molecular-targeted therapies have been hampered due to the lack of robust treatment efficacy in clinical trials. Therefore, there is an urgent need to develop effective therapeutic strategies. In this review, we summarize the molecular profiles of ESCC based on the findings of pivotal comprehensive molecular analyses, highlighting potent therapeutic targets for establishing future precision medicine for ESCC patients, with the most recent results of clinical trials.

show abstract

“…The interim analysis revealed a clinical complete response rate of 42.1%, with a median PFS of 3.2 months and a median OS of 31.0 months. Furthermore, the 12-month PFS and OS rates were 29.6% and 65.8%, respectively ( 47 , 74 ). Another study evaluating Camrelizumab as consolidation immunotherapy also demonstrated promising efficacy and manageable toxicity.…”

Section: Clinical Trials Testing the Combination Of Radiotherapy With...mentioning

confidence: 99%

Radiotherapy combined with immune checkpoint inhibitors in locally advanced/metastatic esophageal squamous cell carcinoma: clinical trials, efficacy and future directions

Jiang

Liu

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Esophageal squamous cell carcinoma (ESCC) is a common malignancy worldwide and often diagnosed at advanced stages with poor prognosis. Combination of radiotherapy and immunotherapy seems to be a promising approach for treating ESCC. This comprehensive review article summarizes the current state of combination of radiotherapy and immunotherapy in locally advanced/metastatic ESCC, delineates the clinical trials that merit attention, and outlines unresolved issues and future research directions in this field. The clinical trial findings suggest that radio-immunotherapy combination may improve tumor response and overall survival with manageable side effects, highlighting the importance of patient selection and the necessity for further research to optimize treatment strategies. Issues such as irradiation dosage, fractionation regimen, irradiation site and technique of radiotherapy, as well as the timing, sequence and duration of combination therapy will all affect treatment outcomes, justifying further in-depth investigation.

show abstract

1211P A multicenter phase II study of atezolizumab monotherapy following definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma (EPOC1802)

Cited by 9 publications

References 0 publications

Current and future on definitive concurrent chemoradiotherapy for inoperable locally advanced esophageal squamous cell carcinoma

Current and future on definitive concurrent chemoradiotherapy for inoperable locally advanced esophageal squamous cell carcinoma

Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma

Radiotherapy combined with immune checkpoint inhibitors in locally advanced/metastatic esophageal squamous cell carcinoma: clinical trials, efficacy and future directions

Contact Info

Product

Resources

About